Granules India Ltd.
Fundamentals
- Market cap
- ₹18,937 cr
- P/E
- 31.83×
- ROE
- 13.50%
- Debt / equity
- 0.35
- Div yield
- 0.23%
- 52-week range
- 432.60 — 804.30
Company snapshot
Granules India Ltd.
Pharmaceuticals
₹20,878 cr
P/E 31.52×
Latest quarter · Jun 2026
Sales₹1,477 cr
Net profit₹180 cr
Op. margin+22.9%
EPS₹7.26
Strength & growth
Debt / equity0.26×
Current ratio1.80×
Sales CAGR+14.9%
EPS CAGR+15.8%
The timeline — 3 notes on Granules India Ltd.
July 2026
- 27 Jul 26 · 12:05 PM IST Brief Brief · Earnings · Mid cap
Granules India submits Q1 FY27 earnings transcript — no new material
A routine transcript filing adds nothing beyond what was discussed on the live July 21 call. The company's next catalysts are the LUMRYZ FTF and FDA observations.
- 06 Jul 26 · 8:37 AM IST Lead Lead · Mid cap
Granules India locks in sole FTF for generic LUMRYZ
The company's second sole first-to-file ANDA positions it for 180-day exclusivity in the U.S. narcolepsy market and strengthens its complex generics franchise.